NOV-002 / Cellectar - LARVOL DELTA

Association of Claudin-1(CLDN1) expression with tumor-immune microenvironment (TIME) and survival in locoregionally advanced nasopharyngeal carcinoma (LA-NPC): Implications on therapeutic strategy (ESMO Asia 2025) - P | "Funding: National Medical Research Council (NMRC) Clinician Scientist Award (CSAINV20nov-0021); National Cancer Centre Singapore (NCCS) Cancer Fund, Duke-NUS Oncology Academic Program Goh Foundation Proton Research Programme; Kua Hong Pak Head and Neck Cancer Research Programme, National Medical Research Council (NMRC) Open Fund-Large Collaborative Grant (OF-LCG) (OFLCG21Jun-0013)... Our data suggest an inverse relationship between CLDN1 expression and immune state of the TIME in NPC, and CLDN1 may be a prognostic biomarker in N2-3 LA-NPC. These are pertinent considerations for combinatorial therapeutic strategies of anti-CLDN1 and immune checkpoint blockade in NPC."

Metastases • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • CD4 • CD8 • CLDN1

Claudin-1 (CLDN1) expression in nasopharyngeal carcinoma (NPC): Association with immune exclusion and implications for immune checkpoint inhibitor (ICI) therapy (ESMO Asia 2024) - "Funding National Medical Research Council Singapore Clinician Scientist Award (NMRC/CSA-INV/0027/2018, CSAINV20nov-0021), Duke-NUS Oncology Academic Program, Goh Foundation Proton Research Program, NCCS Cancer Fund, Kua Hong Pak Head and Neck Cancer Research Program...Conclusions Here, we report the overexpression of CLDN1 in NPC that is associated with an immune-low TIME and high PD-L1 expression. Given the role of the tumour TIME in ICI response, our findings provide a rationale for future trials investigating combination of CLDN1 targeting with ICI to reverse this immune exclusion effect, potentially leading to improved outcomes."

Checkpoint inhibition • IO biomarker • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • CD20 • CD68 • CD8 • CLDN1 • PD-L1

Effectiveness of immune checkpoint inhibitors and other treatment modalities in patients with advanced mucosal melanomas: a systematic review and individual patient data meta-analysis. (PubMed, EClinicalMedicine) - "While combining anti-PD1 with other treatment options such as anti-CTLA4, VEGF inhibitors or radiotherapy might achieve better outcomes, these improvements did not reach statistical significance when evaluated by HR, RMTL and RMST ratios. This work was supported by the National Medical Research Council Transition Award (TA20nov-0020), SingHealth Duke-NUS Oncology Academic Clinical Programme (08/FY2020/EX/67-A143 and 08/FY2021/EX/17-A47), the Khoo Pilot Collaborative Award (Duke-NUS-KP(Coll)/2022/0020A), the National Medical Research Council Clinician Scientist-Individual Research Grant-New Investigator Grant (CNIGnov-0025), the Terry Fox Grant (I1056) and the Khoo Bridge Funding Award (Duke-NUS-KBrFA/2024/0083I)."

Checkpoint inhibition • Journal • Metastases • Retrospective data • Review • CNS Disorders • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor

Claudin-1 (CLDN1) tight junction protein expression delineates distinct immune infiltrates in ascending (A) vs descending (D) subtypes of nasopharyngeal carcinoma: Potential implications for treatment selection (ESMO 2024) - "Funding: National Medical Research Council Singapore: Clinician Scientist Award (NMRC/CSA-INV/0027/2018, CSAINV20nov-0021), Duke-NUS Medical School: Oncology Academic Program, Goh Foundation Proton Research Program, National Cancer Centre Singapore: NCCS Cancer Fund, Kua Hong Pak Head and Neck Cancer Research Program... Resolving tumor heterogeneity can improve upon current therapy. The data presented here confirm that A vs D subtypes have distinct IC composition and PD-L1 expression suggesting potential differences in benefit from checkpoint inhibitors. CLDN1 expression presents another layer of heterogeneity that delineates an immune excluded subpopulation within each subtype."

IO biomarker • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • CD4 • CD8 • CLDN1 • PD-L1

BrainFocus iEEG: A Cloud-Based Software to Assist Clinicians in Identifying Seizure Onset Zone(s) in Drug-Resistant Patients (AES 2023) - "2021INNOV00027)... The use of BrainFocus can assist clinicians in the diagnosis of epileptic patients with iEEG, allowing SOZ validation in simple cases and revealing relevant epileptogenic patterns that might be invisible to the human eye in challenging cases."

Clinical • CNS Disorders • Epilepsy

Angioimmunoblastic T cell lymphoma prognostic index in Asian population identifies low risk patients with unique gene expression profiles (ICML 2023) - "The research was funded by: NCCS Cancer Fund (Research) (NCCSCF-R-YR2021-JUN-SSD1), Tanoto Foundation Professorship in Medical Oncology, New Century Foundation Limited, Ling Foundation, Singapore Ministry of Health’s National Medical Research Council Research Transition Awards (TA21jun-0005 and TA20nov-0020), Large Collaborative Grant (OFLCG18May-0028), and Collaborative centre grant (TETRAD II)... Our AITL-PI identified 3 different subgroups of patients with disparate outcomes based on their presenting clinical parameters. Low risk patients had 5-year OS exceeding 80%. Gene expression profiling found unique immune and oncogenic signalling profiles in the low risk group that would allow for further dissection in future molecular analyses."

Clinical • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • TGFB1

Comparative transcriptomic analyses of 100,691 primary tumors from East Asian (EA) and North American (NA) men with prostate cancer (PCa) (ESMO 2022) - "Funding National Medical Research Council Singapore Clinician Scientist Award (NMRC/CSA-INV/0027/2018, CSAINV20nov-0021), National Research Foundation Proton Competitive Research Program (NRF-CRP17-2017-05), Ministry of Education Tier 3 Academic Research Fund (MOE2016-T3-1-004), the Duke-NUS Oncology Academic Program Goh Foundation Proton Research Programme, NCCS Cancer Fund, and the Kua Hong Pak Head and Neck Cancer Research Programme...Luminal B and PCa with high angiogenesis scores had worse DMFS (HR 2.98 [0.9-10.2]; HR 6.06 [1.3-28.2], respectively) in the EA cohort. Conclusions Herein, we validated the Decipher GC for prognostication, and using a large reference population of NA PCa tumors, identified several demographic-specific transcriptomic features, which may have implications on the efficacy of new therapeutic agents in EA men with PCa."

Genito-urinary Cancer • Head and Neck Cancer • Oncology • Prostate Cancer • Solid Tumor • PD-L2 • PTEN

Mortality of early treatment for radiation-induced brain necrosis in head and neck cancer survivors: A multicentre, retrospective, registry-based cohort study. (PubMed, EClinicalMedicine) - P=N/A | "Patients who had tumor progression before the diagnosis of RN, underwent surgical brain necrosis lesions resection before corticosteroids and/or bevacizumab treatment, had intracranial metastases before the diagnosis of RN, lacked follow-up data, or had a follow-up period of less than three months were excluded. In the absence of data from randomised trials, our study will have an important implication for clinicians regarding the optimal timing of treatment for RN, and provides the foundation and supporting data for future trials on this topic. National Natural Science Foundation of China (81925031, 81820108026, 81872549, 81801229, 82003389), the Science and Technology Program of Guangzhou (202007030001), Young Teacher Training Program of Sun Yat-sen University (20ykpy106), Key-Area Research and Development Program of Guangdong Province (2018B030340001), the National Medical Research Council Singapore Clinician Scientist Award (NMRC/CSA-INV/0027/2018,..."

Journal • Retrospective data • Cardiovascular • Head and Neck Cancer • Immunology • Oncology • Solid Tumor